Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

December 4, 2019

Study Completion Date

April 26, 2022

Conditions

Stage IA Pancreatic CancerStage IB Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic Cancer

Interventions

RADIATION

stereotactic body radiation therapy

Undergo SBRT

DRUG

capecitabine

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo definitive surgery

PROCEDURE

magnetic resonance imaging

Optional correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors

lead

University of Wisconsin, Madison

OTHER

NCT01918644 - Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter